Stockreport

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF – Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of sch [Read more]